Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986288 |
Synonyms | |
Therapy Description |
BMS-986288 is a CTLA4 antibody, combined with a masking peptide that is cleaved in the tumor microenvironment, that prevents suppression of T-cell activation (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986288 | BMS986288|BMS 986288 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | BMS-986288 is a CTLA4 antibody, combined with a masking peptide that is cleaved in the tumor microenvironment, that prevents suppression of T-cell activation (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03994601 | Phase Ib/II | BMS-986288 BMS-986288 + Nivolumab | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Completed | USA | ITA | FRA | ESP | CAN | ARG | 1 |